MedTrace Logo

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

NCT05702788 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-04-26

No results posted yet for this study

Summary

This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.

Conditions

Interventions

DRUG

Jaktinib hydrochloride tablets

75mg of Jaktinib administered orally Twice daily(BID) with best available treatment.

DRUG

Jaktinib hydrochloride tablets

100mg of Jaktinib administered orally Twice daily(BID) with best available treatment.

OTHER

Placebo

Placebo (given as two placebo tablets) administered orally BID with best available treatment.

Sponsors & Collaborators

  • Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Hongzhou Lu · The Third People Hospital of Shenzhen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2024-04-23
Completion
2024-04-23

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05702788 on ClinicalTrials.gov